Anavex Life Sciences Corp (AVXL)

[WilliamMunny]

In regard to whether a company can sit long on a “good news” trial result, let’s remember that Biogen’s counsel had to persuade CTAD to allow them to get an exemption on that organization’s embargo in order to release their AD trial results (or at least the highlights) prior to their presentation. That exemption was based on the SEC’s material information rules we are discussing here. If that really applies to Biogen’s results, it would certainly apply to similar or better results from Anavex, whose stock would surely enjoy a higher percentage gain, given the far smaller size of the company.